January 07, 2019
WELLESLEY, Mass., Jan. 07, 2019 – As a result of the rising incidence of blood cancer, increased funding for cancer treatment and the development of highly sensitive tests, the global blood cancer therapeutics market is progressing at a rapid rate, according to the report “Blood Cancer Therapeutics: Global Markets to 2023.”
According to BCC Research, the global market for blood cancer therapeutics was valued at $38.5 billion in 2018 and is expected to reach $64.8 billion by 2023 at a compound annual growth rate (CAGR) of 11.0% during the forecast period.
Major players in the market include: Roche Holding AG (RHHBY), Novartis (NVS), Celgene Corp. (CELG), Pfizer Inc. (PFE), Bristol-Meyers Squibb Co. (BMY), Johnson and Johnson (JNJ), Merck & Co., Inc. (MRK), AstraZeneca plc (AZNCF), Eli Lilly and Company (LLY), Takeda Pharmaceutical Co. Ltd (TKPHF), Astellas Pharma Inc. (ALPMF), AbbVie (ABBV) and Sanofi.
“Governments and non-government organizations (NGOs) have launched several screening and testing programs to diagnose blood cancer,” the report states. “Early blood cancer diagnosis and prompt, effective treatment can reduce risk of leukemia, lymphoma and myeloma transmission, and deliver clinical benefits.”
Expansion Within the Global Leukemia Therapeutic Market
The global leukemia therapeutic market is expected to reach $23.2 billion by 2023. The market holds tremendous growth opportunities due to an increase in public and private initiatives to diagnose the disease, a rise in the number of biopsies conducted annually and the availability of novel drugs.
Editors/reporters requesting analyst interviews should contact Eric Surber at email@example.com.
Blood Cancer Therapeutics: Global Markets to 2023( PHM210A )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.